SLC5A2 and diabetes mellitus: When combined with metformin, the DPP-4 inhibitor (vildagliptin) and the SGLT2 inhibitor (empagliflozin) have a significant beneficial effect on diabetes management and play a vital role in lowering body weight and maintaining the lipid profile.